111 related articles for article (PubMed ID: 22421368)
1. A dramatic fetal outcome following transplacental transfer of dasatinib.
Berveiller P; Andreoli A; Mir O; Anselem O; Delezoide AL; Sauvageon H; Chapuis N; Tsatsaris V
Anticancer Drugs; 2012 Aug; 23(7):754-7. PubMed ID: 22421368
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
3. Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib.
Oweini H; Otrock ZK; Mahfouz RA; Bazarbachi A
Arch Gynecol Obstet; 2011 Jan; 283(1):133-4. PubMed ID: 20473616
[TBL] [Abstract][Full Text] [Related]
4. [Dasatinib. A novel tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia].
Bjerrum OW; Dufva IH; Stentoft J; Hasselbalch HC
Ugeskr Laeger; 2008 Jan; 170(5):331-3. PubMed ID: 18252160
[TBL] [Abstract][Full Text] [Related]
5. Successful pregnancy in a patient with chronic myeloid leukaemia exposed to dasatinib during the first trimester.
Bayraktar S; Morency B; Escalón MP
BMJ Case Rep; 2010 Oct; 2010():. PubMed ID: 22791487
[TBL] [Abstract][Full Text] [Related]
6. Pleural effusions due to dasatinib.
Brixey AG; Light RW
Curr Opin Pulm Med; 2010 Jul; 16(4):351-6. PubMed ID: 20375898
[TBL] [Abstract][Full Text] [Related]
7. Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.
Tyler T
Ann Pharmacother; 2009 May; 43(5):920-7. PubMed ID: 19336654
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events.
Shayani S
Ther Drug Monit; 2010 Dec; 32(6):680-7. PubMed ID: 20864900
[TBL] [Abstract][Full Text] [Related]
9. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series.
Bergeron A; Réa D; Levy V; Picard C; Meignin V; Tamburini J; Bruzzoni-Giovanelli H; Calvo F; Tazi A; Rousselot P
Am J Respir Crit Care Med; 2007 Oct; 176(8):814-8. PubMed ID: 17600277
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
11. Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia.
Caocci G; Atzeni S; Orrù N; Azzena L; Martorana L; Littera R; Ledda A; La Nasa G
Leukemia; 2008 Nov; 22(11):2127-8. PubMed ID: 18463676
[No Abstract] [Full Text] [Related]
12. Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats.
He K; Lago MW; Iyer RA; Shyu WC; Humphreys WG; Christopher LJ
Drug Metab Dispos; 2008 Dec; 36(12):2564-70. PubMed ID: 18787054
[TBL] [Abstract][Full Text] [Related]
13. Acute renal failure under dasatinib therapy.
Ozkurt S; Temiz G; Acikalin MF; Soydan M
Ren Fail; 2010 Jan; 32(1):147-9. PubMed ID: 20113282
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib in chronic myelogenous leukemia.
Kathula SK
N Engl J Med; 2006 Sep; 355(10):1062; author reply 1063-4. PubMed ID: 16957155
[No Abstract] [Full Text] [Related]
15. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
16. Reversible pre-capillary pulmonary hypertension due to dasatinib.
Buchelli Ramirez HL; Álvarez Álvarez CM; Rodríguez Reguero JJ; García Clemente MM; Casan Clarà P
Respir Care; 2014 May; 59(5):e77-80. PubMed ID: 24149673
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.
Luo FR; Yang Z; Camuso A; Smykla R; McGlinchey K; Fager K; Flefleh C; Castaneda S; Inigo I; Kan D; Wen ML; Kramer R; Blackwood-Chirchir A; Lee FY
Clin Cancer Res; 2006 Dec; 12(23):7180-6. PubMed ID: 17145844
[TBL] [Abstract][Full Text] [Related]
18. Response to treatment in women with chronic myeloid leukemia during pregnancy and after delivery.
Klamová H; Marková M; Moravcová J; Sisková M; Cetkovský P; Machová Poláková K
Leuk Res; 2009 Nov; 33(11):1567-9. PubMed ID: 19580997
[TBL] [Abstract][Full Text] [Related]
19. Imatinib use during pregnancy and breast feeding: a case report and review of the literature.
Ali R; Ozkalemkas F; Kimya Y; Koksal N; Ozkocaman V; Gulten T; Yorulmaz H; Tunali A
Arch Gynecol Obstet; 2009 Aug; 280(2):169-75. PubMed ID: 19083009
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily.
Sillaber C; Herrmann H; Bennett K; Rix U; Baumgartner C; Böhm A; Herndlhofer S; Tschachler E; Superti-Furga G; Jäger U; Valent P
Eur J Clin Invest; 2009 Dec; 39(12):1098-109. PubMed ID: 19744184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
